Status Epilepticus Treatment Algorithm
Administer IV lorazepam 4 mg at 2 mg/min immediately for any actively seizing patient, followed by a second-line anticonvulsant within 5–10 minutes if seizures persist, and escalate to anesthetic agents if refractory after 20 minutes. 1, 2
Stage 1: Immediate First-Line Treatment (0–5 minutes)
Benzodiazepine Administration
- IV lorazepam 4 mg at 2 mg/min is the preferred first-line agent, terminating status epilepticus in approximately 65% of cases 1, 2
- Lorazepam demonstrates superior efficacy compared to diazepam (59.1% vs 42.6% seizure cessation) and has a longer duration of action 1
- Repeat the lorazepam dose after at least 1 minute if seizures continue, with a maximum of 2 total doses 1
Alternative Routes When IV Access Unavailable
- IM midazolam 10 mg provides equivalent efficacy to IV lorazepam and is superior when IV access is delayed 1, 3
- Intranasal or buccal midazolam are acceptable alternatives, though with slightly lower evidence quality 2, 3
- Never use IM diazepam due to erratic absorption; use rectal diazepam 0.5 mg/kg instead if IM administration is being considered 1
Critical Safety Measures
- Have airway equipment (bag-valve-mask, intubation set) immediately available before administering any benzodiazepine, as respiratory depression is a predictable adverse effect 1, 2
- Maintain continuous oxygen saturation monitoring throughout treatment 2, 4
- Provide high-flow oxygen and assess airway, breathing, and circulation before drug administration 1
Concurrent Actions
- Check fingerstick glucose immediately and correct hypoglycemia, a rapidly reversible cause 1
- Begin searching for underlying etiologies: hyponatremia, hypoxia, drug toxicity/withdrawal, CNS infection, stroke, or intracerebral hemorrhage 1, 2
Stage 2: Second-Line Treatment (5–20 minutes)
If seizures persist after adequate benzodiazepine dosing, immediately escalate to one of the following second-line agents without delay. 1, 2
The 2019 ESETT trial demonstrated no statistically significant difference in efficacy among levetiracetam, fosphenytoin, and valproate (seizure cessation rates 47%, 45%, and 46% respectively), so agent selection should prioritize safety profile and contraindications rather than efficacy alone 1
Preferred Second-Line Agents (Ordered by Safety Profile)
Valproate (Safest Cardiovascular Profile)
- Dose: 20–30 mg/kg IV (maximum 3000 mg) over 5–20 minutes 1, 2
- Efficacy: 88% seizure control with 0% hypotension risk 1
- Superior safety profile compared to phenytoin in head-to-head trials 1
- Absolute contraindication in women of childbearing potential due to fetal teratogenicity 1
Levetiracetam (Minimal Cardiovascular Effects)
- Dose: 30 mg/kg IV (maximum 2500–3000 mg) over 5 minutes 1, 2
- Efficacy: 68–73% seizure control with ~0.7% hypotension risk 1
- No cardiac monitoring required, making it ideal for elderly patients 1
- Intubation rate approximately 20% 1
Fosphenytoin (Traditional Option)
- Dose: 20 mg PE/kg IV at maximum rate of 150 PE/min 1, 2
- Efficacy: 84% seizure control but 12% hypotension risk 1
- Requires continuous ECG and blood pressure monitoring 1, 2
- Intubation rate approximately 26% 1
- Preferred over phenytoin due to faster administration and less cardiovascular toxicity 1
Phenobarbital (Reserve Option)
- Dose: 20 mg/kg IV over 10 minutes (maximum 1000 mg) 1
- Efficacy: 58.2% seizure control as initial second-line agent 1
- Higher risk of respiratory depression and hypotension due to vasodilatory and cardiodepressant effects 1, 2
Critical Pitfall to Avoid
- Never skip directly to third-line anesthetic agents (pentobarbital, propofol) until benzodiazepines and at least one second-line agent have been tried 1
- Do not use neuromuscular blockers alone (e.g., rocuronium), as they only mask motor manifestations while allowing continued electrical seizure activity and brain injury 1
Stage 3: Refractory Status Epilepticus (20+ minutes)
Refractory status epilepticus is defined as seizures continuing despite benzodiazepines and one second-line agent. 1, 2
Immediate Actions
- Transfer to ICU immediately for advanced management 1
- Initiate continuous EEG monitoring to guide anesthetic titration and detect non-convulsive seizure activity 1, 2, 5
- Load with a long-acting anticonvulsant (phenytoin/fosphenytoin, valproate, levetiracetam, or phenobarbital) during anesthetic infusion to ensure adequate levels before tapering 1
Third-Line Anesthetic Agents
Midazolam Infusion (First Choice)
- Loading dose: 0.15–0.20 mg/kg IV 1, 2, 4
- Maintenance infusion: start at 1 mg/kg/min, titrate up by 1 mg/kg/min every 15 minutes to maximum 5 mg/kg/min 1, 2, 4
- Efficacy: 80% seizure control with 30% hypotension risk 1, 2
- Lower hypotension risk compared to pentobarbital (30% vs 77%) 1
Propofol (Alternative for Intubated Patients)
- Loading dose: 2 mg/kg IV bolus 1, 2
- Maintenance infusion: 3–7 mg/kg/hour 1, 2
- Efficacy: 73% seizure control with 42% hypotension risk 1, 2
- Requires mechanical ventilation but shorter duration than barbiturates (4 days vs 14 days) 1
- Continuous blood pressure monitoring essential 1
Pentobarbital (Highest Efficacy, Highest Complication Rate)
- Loading dose: 13 mg/kg IV 1
- Maintenance infusion: 2–3 mg/kg/hour 1
- Efficacy: 92% seizure control but 77% hypotension risk requiring vasopressor support 1
- Mean mechanical ventilation duration of 14 days 1
- Reserved for cases failing midazolam or propofol 1
Monitoring Requirements
- Continuous EEG throughout tapering and for at least 24–48 hours after discontinuation, as breakthrough seizures occur in >50% of patients and are often only detectable by EEG 1, 5
- Continuous vital sign monitoring, particularly respiratory status and blood pressure 2
- Prepare for mechanical ventilation before initiating any anesthetic agent 2
Super-Refractory Status Epilepticus (Beyond 24 hours)
Fourth-Line Options
- Ketamine demonstrates 64% efficacy when administered early in refractory SE (within 3 days), but efficacy drops to 32% when delayed to mean 26.5 days 1
- Dosing range: 0.45–2.1 mg/kg/hour, with maximal daily doses of 1392–4200 mg based on clinical response 1
- Acts on NMDA receptors, providing mechanistically distinct approach from GABA-ergic agents 1
Immunotherapy Considerations
- If autoimmune or paraneoplastic etiology is suspected, or no etiology identified (cryptogenic new-onset refractory status epilepticus/NORSE), early treatment with immunomodulatory agents is recommended 6, 7
Maintenance Dosing After Seizure Control
Lorazepam
- 0.05 mg/kg IV (maximum 1 mg) every 8 hours for three doses 1
Levetiracetam
- Convulsive SE: 30 mg/kg IV every 12 hours OR increase prophylaxis dose by 10 mg/kg (to 20 mg/kg) IV every 12 hours (maximum 1500 mg) 1
- Non-convulsive SE: 15 mg/kg IV every 12 hours (maximum 1500 mg) 1
Phenobarbital
- 1–3 mg/kg IV every 12 hours 1